Human post-mortem striatal α4β2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome

被引:90
作者
Durany, N
Zöchling, R
Boissl, KW
Paulus, W
Ransmayr, G
Tatschner, T
Danielczyk, W
Jellinger, K
Deckert, J
Riederer, P
机构
[1] Univ Int Catalunya, E-08190 Barcelona, Spain
[2] Univ Wurzburg, Dept Psychiat, D-97080 Wurzburg, Germany
[3] State Hosp Neurol & Psychiat, D-3362 Mauer, Germany
[4] Univ Munster, Inst Neuropathol, D-48149 Munster, Germany
[5] Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria
[6] Univ Wurzburg, Inst Forens Med, D-97078 Wurzburg, Germany
[7] PKH, Ludwig Boltzmann Inst Clin Neurobiol, A-1140 Vienna, Austria
[8] Ludwig Boltzmann Inst Aging Res, Vienna, Austria
[9] Geriatr Ctr Wienerwald, Dept Neurobiol, A-1130 Vienna, Austria
关键词
nicotine; alpha 4 beta 2 nicotinic acetylcholine receptors; schizophrenia; Parkinson's syndrome;
D O I
10.1016/S0304-3940(00)01144-7
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The density of nicotinic alpha 4 beta 2 receptors, which are believed to largely mediate nicotine's effects, has been reported to be decreased in post-mortem hippocampus of patients with schizophrenia. In the present study, using [H-3]cytisine as a radioligand, we observed a significant 30% decrease in post-mortem striatum of patients with schizophrenia (n = 12) as compared to controls (n = 12). A 25% decrease of striatal alpha 4 beta 2 receptor density in patients with Parkinson's syndrome (n = 12) was not significant. As an upregulation of alpha 4 beta 2 receptors has been observed due to nicotine consumption, the beneficial effects of nicotine described in patients with schizophrenia may be partly due to a compensation for a decrease in alpha 4 beta 2 nicotinic acetylcholine receptors. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:109 / 112
页数:4
相关论文
共 22 条
  • [1] ADLER LE, 1993, AM J PSYCHIAT, V150, P1856
  • [2] COMPARATIVE ALTERATIONS OF NICOTINIC AND MUSCARINIC BINDING-SITES IN ALZHEIMERS AND PARKINSONS DISEASES
    AUBERT, I
    ARAUJO, DM
    CECYRE, D
    ROBITAILLE, Y
    GAUTHIER, S
    QUIRION, R
    [J]. JOURNAL OF NEUROCHEMISTRY, 1992, 58 (02) : 529 - 541
  • [3] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [4] Nicotine dependence in schizophrenia: Clinical phenomena and laboratory findings
    Dalack, GW
    Healy, DJ
    Meador-Woodruff, JH
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (11) : 1490 - 1501
  • [5] CIGARETTE-SMOKING AND NEUROLEPTIC-INDUCED PARKINSONISM
    DECINA, P
    CARACCI, G
    SANDIK, R
    BERMAN, W
    MUKHERJEE, S
    SCAPICCHIO, P
    [J]. BIOLOGICAL PSYCHIATRY, 1990, 28 (06) : 502 - 508
  • [6] FLORES CM, 1992, MOL PHARMACOL, V41, P31
  • [7] Inhibition of monoamine oxidase B in the brains of smokers
    Fowler, JS
    Volkow, ND
    Wang, GJ
    Pappas, N
    Logan, J
    MacGregor, R
    Alexoff, D
    Shea, C
    Schlyer, D
    Wolf, AP
    Warner, D
    Zezulkova, I
    Cilento, R
    [J]. NATURE, 1996, 379 (6567) : 733 - 736
  • [8] EVIDENCE IN POSTMORTEM BRAIN-TISSUE FOR DECREASED NUMBERS OF HIPPOCAMPAL NICOTINIC RECEPTORS IN SCHIZOPHRENIA
    FREEDMAN, R
    HALL, M
    ADLER, LE
    LEONARD, S
    [J]. BIOLOGICAL PSYCHIATRY, 1995, 38 (01) : 22 - 33
  • [9] Smoking and Parkinson's disease - A dose-response relationship
    Gorell, JM
    Rybicki, BA
    Johnson, CC
    Peterson, EL
    [J]. NEUROLOGY, 1999, 52 (01) : 115 - 119
  • [10] CHARACTERIZATION OF [H-3] CYTISINE BINDING TO HUMAN BRAIN MEMBRANE PREPARATIONS
    HALL, M
    ZERBE, L
    LEONARD, S
    FREEDMAN, R
    [J]. BRAIN RESEARCH, 1993, 600 (01) : 127 - 133